Supplementary Table 3. Individual data for participants before and after treatment with the photobiomodulation protocols.

cuppionicinally ru	J.C J	GROUP AA PARTICIPANTS							GROUP AB PARTICIPANTS				
	AA1	AA2	AA3	AA4	AA5	AA6	AB1	AB2	AB3	AB4	AB5	AB6	
NHPT (seconds)													
affected hand 12 weeks prior to treatment							29.0	45.8	19.6	25.1	21.0	24.0	
immediately before treatment	22.5	23.0	21.2	26.1	21.5	21.6	22.2 (23%)	56.5 -(23%)	19.5 (1%)	31.3 -(24%)	22.3 -(6%)	22.8 (5%)	
after 4 weeks treatment (CT) after 12 weeks treatment (CT)	21.1 (6%)	28.6 -(24%)	28.0 -(32%)	37.1 -(42%)	17.9 (17%)	27.1 -(25%)	25.8 (11%) 27.9 (4%)	48.2 -(5%) 47.6 -(4%)	21.5 -(10%)	25.7 -(2%) 34.8 -(38%)	22.3 -(6%) 24.1 -(15%)	19.2 (20%) 23.2 (3%)	
after 26/38 week home treatm			, ,	27.3 -(5%)	21.6 (0%)	29.6 -(37%)	29.4 -(1%)	69.9 -(53%)	22.0 -(12%)	23.4 (7%)	16.4 (22%)	24.4 -(2%)	
dominant hand													
12 weeks prior to treatment immediately before treatment	29.3	18.1	33.7	26.4	16.0	25.7	20.1 18.0 (11%)	30.2 29.1 (4%)	19.6 19.5 (1%)	24.1 26.6 -(10%)	21.9 17.9 (18%)	24.0 22.8 (5%)	
after 4 weeks treatment (CT)							16.5 (18%)	24.9 (18%)	21.5 -(10%)	26.8 -(11%)	18.7 (15%)	19.2 (20%)	
after 12 weeks treatment (CT) after 26/38 week home treatm		17.9 (1%)	27.7 (18%)	26.8 -(2%)	17.7 -(10%) 17.0 -(6%)	20.0 (22%)	25.5 -(27%) 17.1 (15%)	28.3 (6%) 29.6 (2%)	20.5 -(4%)	28.8 -(20%) 28.8 -(20%)	20.1 (8%)	23.2 (3%) 22.5 (6%)	
SPIRAL TEST (seconds)													
dominant hand													
12 weeks prior to treatment immediately before treatment	20.4	23.8	29.3	52.5	22.6	26.2	32.4 29.6 (9%)	37.5 38.2 -(2%)	48.6 28.7 (41%)	33.9 42.0 -(24%)	29.3 20.7 (29%)	36.5 40.3 -(10%)	
after 4 weeks treatment (CT)		23.7 (0%)	31.9 -(9%)	23.2 (56%)		21.1 (19%)	19.4 (40%)	30.8 (18%)	18.7 (61%)	41.7 -(23%)	23.7 (19%)	31.2 (15%)	
after 12 weeks treatment (CT) after 26/38 week home treatm		27.6 -(16%)	31.9 -(9%)	44.2 (16%)	16.5 (27%) 17.4 (23%)		28.9 (11%) 34.4 -(6%)	29.9 (20%) 34.2 (9%)	29.1 (40%) 19.8 (59%)	45.9 -(35%) 35.9 -(6%)	14.1 (52%) 21.1 (28%)	21.7 (41%) 27.9 (24%)	
STEP TEST (number of steps)													
affected foot 12 weeks prior to treatment							17	11	14	9	9	7	
immediately before treatment	12	12	8	14	18	14	21 (24%)	12 (9%)	15 (7%)	13 (44%)	13 (44%)	15 (114%)	
after 4 weeks treatment (CT) after 12 weeks treatment (CT)	15 (25%)	18 (50%)	11 (38%)	20 (43%)	23 (28%)	17 (21%)	23 (35%) 23 (35%)	14 (27%) 14 (27%)	17 (21%) 19 (36%)	15 (67%) 11 (22%)	15 (67%) 16 (78%)	14 (100%) 15 (114%)	
after 26/38 week home treatm	15 (25%)	nd	nd	18 (29%)	21 (17%)	17 (21%)	20 (18%)	12 (9%)	21 (50%)	11 (22%)	18 (100%)	14 (100%)	
dominant foot													
12 weeks prior to treatment immediately before treatment	12	11	9	12	20	14	12 18 (50%)	10 12 (20%)	14 15 (7%)	11 11 (0%)	12 12 (0%)	7 15 (114%)	
after 4 weeks treatment (CT)							21 (75%)	12 (20%)	17 (21%)	15 (36%)	15 (25%)	14 (100%)	
after 12 weeks treatment (CT) after 26/38 week home treatm	14 (17%) 14 (17%)	18 (64%) nd	11 (22%) nd	16 (33%) 20 (67%)	22 (10%) 21 (5%)	17 (21%) 17 (21%)	21 (75%) 24 (100%)	12 (20%) 13 (30%)	19 (36%) 21 (50%)	13 (18%) 13 (18%)	17 (42%) 19 (58%)	15 (114%) 14 (100%)	
TS (seconds)													
affected foot behind													
12 weeks prior to treatment immediately before treatment	30.0	12.0	0.0	0.0	1.0	6.0	8.0 (0%)	0.0 1.0	2.0 7.5 (275%)	4.0 14.0 (250%)	2.0 3.6 (80%)	0.0	
after 4 weeks treatment (CT)			9.5				30.0 (275%)	4.7	30.0 (1400%)	30.0 (650%) 30.0 (650%)	9.0 (350%)	2.7	
after 12 weeks treatment (CT) after 26/38 week home treatm		30.0 (150%) nd	nd	0.0	2.0 (100%) 4.0 (300%)	2.0 -(67%) 3.9 -(34%)	15.0 (88%) 30.0 (275%)	1.0 nd	5.6 (180%) 30.0 (1400%)	3.9 -(2%)	6.0 (200%) 3.4 (70%)	1.0 3.0	
unaffected foot behind													
12 weeks prior to treatment							1.0	0.0	1.0	7.0	4.0	0.0	
immediately before treatment after 4 weeks treatment (CT)		2.0	0.0	0.0	4.0	7.0	9.2 (820%) 30.0 (2900%)	0.0 3.1	4.3 (330%) 3.0 (200%)	4.0 -(43%) 30.0 (329%)	13.0 (225%) 3.0 -(25%)	3.3	
after 12 weeks treatment (CT) after 26/38 week home treatm	24.3 -(19%) 30.0 (0%)	30.0 ##### nd	2.3 nd	1.0 0.0	3.0 -(25%) 2.7 -(33%)	6.0 -(14%) 3.9 -(44%)	30.0 (2900%) 30.0 (2900%)	2.5 nd	2.0 (100%) 10.7 (972%)	20.0 (186%) 30.0 (329%)	2.0 -(50%) 3.4 -(15%)	1.0 3.2	
	1		1	1 2.0	(0077)		1000 (2000),		2011 (012)2	0010 (000)	(-0,1)		
SLS (seconds) affected foot raised													
12 weeks prior to treatment immediately before treatment	6.0	2.0	5.0	0.0	8.0	1.0	8.9 2.0 -(78%)	0.0	0.0 1.1	1.0 3.1 (210%)	2.0 (0%)	2.0 1.0 -(50%)	
after 4 weeks treatment (CT)							30.0 (237%)	0.1	1.3	1.6 (60%)	0.0	1.0 -(50%)	
after 12 weeks treatment (CT) after 26/38 week home treatm	2.6 -(57%) 3.9 -(35%)	14.0 (600%) nd	0.0 nd	0.0	0.0 5.4 -(32%)	2.0 (100%) 1.9 (90%)	10.0 (12%) 23.2 (161%)	0.0 nd	1.6 5.0	5.4 (440%) 2.1 (110%)	0.0 nd	0.0 nd	
unaffected foot raised													
12 weeks prior to treatment							4.9	0.0	0.0	1.0	1.0	1.0	
immediately before treatment after 4 weeks treatment (CT)	5.0	2.0	3.0	1.0	3.0	2.2	12.0 (145%) 6.7 (37%)	0.0	2.1 0.1	3.1 (210%) 1.6 (60%)	2.0 (100%) 0.0	0.7 -(30%)	
after 12 weeks treatment (CT) after 26/38 week home treatm	2.4 -(52%) 18.9 (278%)	2.7 (35%) nd	0.0 nd	12.3 (1130%)	0.0 30.0 (900%)	1.0 -(55%) 30.0 (1264%)	26.0 (431%) 30.0 (512%)	0.0 nd	1.7 5.0	5.4 (440%) 2.1 (110%)	0.0 nd	0.0 nd	
		110	TIG.		30.0 (30070)	30.0 (120470)	30.0 (312/0)	IIu	5.0	2.1 (110/0)	no	iiu	
WALK SPEED (metres/second 12 weeks prior to treatment)						1.22	1.03	1.62	1.20	1.33	0.76	
immediately before treatment after 4 weeks treatment (CT)	1.00	0.86	0.57	1.03	1.33	1.20	1.76 (44%) 1.94 (58%)		1.88 (16%) 2.00 (23%)	1.94 (61%)	1.90 (43%) 2.04 (53%)		
after 12 weeks treatment (CT)		1.62 (89%)	0.79 (39%)		1.94 (45%)		1.94 (58%)	1.60 (56%)	2.21 (36%)	1.94 (61%)	1.96 (47%)	1.50 (98%)	
after 26/38 week home treatm	1.72 (72%)	nd	nd	1.33 (29%)	1.75 (32%)	1.09 -(9%)	2.07 (69%)	1.69 (64%)	2.54 (57%)	1.93 (61%)	2.00 (50%)	1.54 (103%)	
WALK STRIDE LENGTH (metre 12 weeks prior to treatment	s)			ı			0.5	0.5	0.5	0.6	0.6	0.5	
immediately before treatment	0.5	0.5	0.4	0.5	0.6	0.5	0.6 (20%)	0.7 (33%)	0.8 (38%)	0.9 (43%)	0.6 (0%)	0.7 (33%)	
after 4 weeks treatment (CT) after 12 weeks treatment (CT)	0.7 (22%)	0.5 (18%)	0.5 (8%)	0.7 (33%)	0.5 -(23%)	0.8 (38%)	0.4 -(20%)	0.8 (50%) 0.7 (33%)	0.7 (22%) 0.8 (38%)	0.9 (43%) 0.9 (43%)	0.8 (25%) 0.8 (25%)	0.7 (33%)	
after 26/38 week home treatm	0.8 (38%)	nd	nd	0.6 (20%)	0.8 (25%)	0.7 (22%)	0.8 (50%)	0.7 (33%)	0.8 (38%)	0.8 (25%)	0.8 (25%)	0.8 (50%)	
TUG (seconds)													
12 weeks prior to treatment immediately before treatment	10.2	8.0	18.0	11.0	6.5	7.5	7.9 7.4 (6%)	9.7 8.5 (12%)	6.8 6.5 (4%)	7.6 7.3 (4%)	7.8 6.7 (14%)	13.8 9.3 (33%)	
after 4 weeks treatment (CT)							6.4 (19%)	7.4 (24%)	6.3 (7%)	6.6 (13%)	6.5 (17%)	7.9 (43%)	
after 12 weeks treatment (CT) after 26/38 week home treatm	8.4 (18%) 8.1 (21%)	7.1 (11%) nd	15.5 (14%) nd	8.5 (23%) 9.9 (10%)	5.2 (20%) 6.0 (7%)	6.6 (12%) 5.8 (23%)	6.6 (16%) 6.6 (16%)	7.6 (22%) 8.0 (18%)	5.9 (13%) 6.3 (7%)	7.1 (6%) 6.6 (13%)	6.3 (19%) 5.9 (24%)	7.6 (45%) 7.9 (43%)	
TUG MOTOR (seconds)													
12 weeks prior to treatment							8.8	9.0	6.9	7.6	8.3	11.8	
immediately before treatment after 4 weeks treatment (CT)	10.9	8.2	17.7	10.6	7.1	7.2	8.2 (7%) 7.4 (16%)	8.1 (10%) 7.2 (20%)	6.5 (6%) 6.6 (4%)	8.3 -(9%) 6.9 (9%)	6.4 (23%) 6.4 (23%)	9.1 (23%) 8.3 (30%)	
after 12 weeks treatment (CT) after 26/38 week home treatm	8.8 (19%) 8.4 (23%)	8.2 (0%) nd	16.5 (7%) nd	9.3 (12%) 13.3 -(26%)	6.6 (7%) 6.1 (14%)	7.0 (3%) 6.4 (11%)	6.4 (27%) 6.0 (32%)	8.5 (6%) 9.2 -(2%)	6.3 (9%) 7.0 -(1%)	7.1 (7%) 6.8 (10%)	6.6 (20%) 5.8 (30%)	8.1 (31%) 8.4 (29%)	
	0.7 (23/0)			13.3 (20/0)	U.I (1470)	J (11/0)	0.0 (32/0)	J.L (L/0)	7.5 (1/0)	0.0 (10/0)	3.0 (30/0)	J. 7 (23/0)	
TUG COGNITIVE (seconds) 12 weeks prior to treatment							10.3	10.6	7.2	8.7	8.8	13.8	
immediately before treatment	12.0	10.4	23.7	10.5	6.0	7.6	7.5 (27%)	8.8 (17%)	7.3 -(1%)	7.5 (14%)	6.7 (24%)	9.0 (35%)	
after 4 weeks treatment (CT) after 12 weeks treatment (CT)	9.3 (23%)	6.9 (34%)	18.2 (23%)	9.3 (11%)	5.2 (14%)	6.8 (11%)	7.2 (30%) 6.3 (39%)	8.2 (23%) 8.9 (16%)	6.7 (7%) 6.4 (11%)	6.6 (24%) 6.8 (22%)	6.2 (30%) 6.8 (23%)	8.7 (37%) 8.1 (41%)	
after 26/38 week home treatm	8.8 (26%)	nd	nd	9.8 (6%)	5.2 (13%)	5.9 (22%)	6.7 (35%)	9.5 (11%)	6.5 (10%)	6.4 (27%)	6.6 (25%)	8.8 (36%)	
MoCA score							26	20	27	20	2.	21	
12 weeks prior to treatment immediately before treatment	24	26	26	28	27	24	26 29 (12%)	28 29 (4%)	27 27 (0%)	26 26 (0%)	24 28 (17%)	21 24 (14%)	
after 4 weeks treatment (CT) after 12 weeks treatment (CT)	25 (4%)	26 (0%)	28 (8%)	28 (0%)	27 (0%)	29 (21%)	28 (8%) 29 (12%)	30 (7%) 30 (7%)	28 (4%) 27 (0%)	26 (0%) 27 (4%)	28 (17%) 29 (21%)	25 (19%) 29 (38%)	
after 26/38 week home treatm		29 (12%)	nd nd	30 (7%)	28.7 (6%)	30 (24%)	30 (15%)	30 (7%)	30 (11%)	28.7 (10%)	30 (25%)	nd nd	

NHPT = nine-hole peg test
TS = tandem stance (eyes closed)
SLS = single leg stance (eyes closed)
TUG = timed up-and-go
MoCA = Montreal Cognitive Assessment
number in brackets is the percentage improvement (positive value) or decline (negative value) in an outcome measure